Hội nghị công bố kết quả kinh doanh quý 3 năm 2026 của Viemed Healthcare (VMD): Tăng trưởng doanh thu và cập nhật định hướng

Những điểm nổi bật

• Viemed Healthcare báo cáo doanh thu kỷ lục trong quý 3/2026 đạt 80,7 triệu USD, tăng 12,2% so với cùng kỳ năm trước và tăng 3,3% so với quý trước.
• Lợi nhuận ròng thuộc về Viemed tăng 32% so với cùng kỳ năm trước lên 4,6 triệu USD, tương đương 0,11 USD trên mỗi cổ phiếu pha loãng. EBITDA điều chỉnh tăng khoảng 6% lên 17,1 triệu USD.
• Số lượng bệnh nhân điều trị PAP đạt 43.861 người, tăng 37,5% so với cùng kỳ năm trước, trong khi số bệnh nhân tái cung ứng vật tư tăng khoảng 22% lên 40.918 người.
• Doanh thu cho thuê máy thở tăng 7,4% so với cùng kỳ năm trước lên 37,5 triệu USD, bất chấp các hoạt động đào tạo và tuân thủ đang diễn ra liên quan đến quy định chi trả sửa đổi của CMS.
• Ban lãnh đạo đã nâng mức cận dưới của dự báo doanh thu cả năm lên 316 triệu - 320 triệu USD và thu hẹp dự báo EBITDA điều chỉnh xuống còn 64 triệu - 66 triệu USD.
• Viemed dự kiến mở rộng dịch vụ chăm sóc sức khỏe bà mẹ sang thêm hai bang mỗi quý kể từ quý 4/2026, đồng thời nhấn mạnh rằng mỗi thị trường sẽ cần lộ trình phát triển kéo dài nhiều năm.

Dữ liệu tài chính chủ chốt

Trong 9 tháng đầu năm 2026, dòng tiền từ hoạt động kinh doanh đạt 35,5 triệu USD và dòng tiền tự do đạt 15,2 triệu USD. Dòng tiền tự do trong 12 tháng gần nhất đạt khoảng 26,1 triệu USD.

Kết quả kinh doanh và hoạt động

Điều trị giấc ngủ là động lực tăng trưởng chính. Viemed đã phục vụ 43.861 bệnh nhân điều trị PAP trong quý, cao hơn 6.000 bệnh nhân so với quý 2 và tăng 37,5% so với cùng kỳ năm trước. Số ca thiết lập máy PAP mới cũng tăng ở cả quy mô so với quý trước và so với cùng kỳ năm trước.

Số lượng bệnh nhân tái cung ứng vật tư tăng 10,5% so với quý trước và tăng khoảng 22% so với cùng kỳ năm trước lên 40.918 người. Ban lãnh đạo kỳ vọng yếu tố mùa vụ thuận lợi trong quý 4 và sự chuyển đổi từ các ca thiết lập máy PAP gần đây sang nhu cầu tái cung ứng. Các đơn hàng tái cung ứng PAP đã tăng 12% so với quý trước.

Doanh thu cho thuê máy thở đạt 37,5 triệu USD, so với mức 36,4 triệu USD trong quý 2 và 35,4 triệu USD trong quý 1. Doanh thu cao hơn 7,4% so với cùng kỳ năm trước, nhờ số lượng bệnh nhân trung bình cao hơn. Ban lãnh đạo cho biết số lượng bệnh nhân vào cuối quý có những biến động nhất thời do yếu tố thời điểm và các xu hướng hiện tại cho thấy đà tăng so với quý trước trong quý 4.

Doanh số bán thiết bị và vật tư y tế tăng khoảng 23,7% so với cùng kỳ năm trước, nhờ mảng điều trị giấc ngủ và sức khỏe phụ nữ. Doanh thu cho thuê các thiết bị khác tăng khoảng 13,1%. Doanh số bán hàng và dịch vụ chiếm 32% doanh thu, tăng từ mức 30,1% của cùng kỳ năm trước.

Sự chuyển dịch sang mảng bán thiết bị và vật tư y tế đã gây áp lực lên biên lợi nhuận gộp do các sản phẩm này thường có biên lợi nhuận thấp hơn so với mảng cho thuê. Tuy nhiên, chúng đòi hỏi ít vốn hơn. Viemed dự kiến chi phí tiết kiệm được từ mạng lưới phân phối mở rộng sẽ đóng góp thêm khoảng 50 điểm cơ bản vào biên lợi nhuận gộp sau khi được triển khai đầy đủ.

Ở mảng chăm sóc sức khỏe bà mẹ, Viemed dự kiến mở rộng thêm hai bang mỗi quý kể từ quý 4. Ban lãnh đạo cho biết các thị trường mới có thể nhanh chóng bắt đầu tạo ra doanh thu thông qua tiếp thị kỹ thuật số, nhưng việc phát triển hợp đồng, tuyển dụng nhân sự địa phương và chuyển đổi giới thiệu bệnh nhân cần một lộ trình dài hơn. Texas, bang mở rộng đầu tiên, tiếp tục duy trì đà tăng trưởng trong suốt cả năm.

Dự báo của ban lãnh đạo

Ban lãnh đạo kỳ vọng cả doanh thu và EBITDA điều chỉnh đều sẽ tăng trưởng so với quý trước trong quý 4. Triển vọng này chưa bao gồm các thương vụ mua lại tiềm năng và các giao dịch chiến lược khác.

Công ty cho biết đóng góp ngày càng tăng từ các sản phẩm và dịch vụ ít thâm dụng vốn hơn sẽ giúp giảm nhu cầu đầu tư vào thiết bị. Trong vài năm tới, ban lãnh đạo dự định sẽ ngày càng tập trung hơn vào lợi nhuận ròng và dòng tiền tự do thay vì một mục tiêu biên EBITDA điều chỉnh cụ thể, đồng thời cho biết biên EBITDA điều chỉnh dự kiến sẽ duy trì trên mức 20% trong thời gian tới.

Rủi ro và các lĩnh vực cần theo dõi

Các khoản phải thu tăng do thời điểm thanh toán liên quan đến kiểm toán, sự chậm trễ trong chuyển đổi hệ thống cùng các yếu tố khác về lập hóa đơn và thu tiền. Ban lãnh đạo khẳng định doanh thu liên quan vẫn hoàn toàn có khả năng thu hồi và viện dẫn hoạt động thu tiền khả quan trong tháng 10, đồng thời kỳ vọng tác động về mặt thời điểm này sẽ được tháo gỡ trong quý 4.

Hoạt động thực thi quy định và kiểm toán yêu cầu bồi thường trong ngành đã gia tăng, làm phát sinh thêm chi phí hành chính và chuyên môn, đồng thời đôi khi kéo dài thời gian thanh toán. Viemed cho biết tỷ lệ kiểm toán thành công của công ty vẫn ở mức cao, nhưng các đội ngũ đang phân bổ thêm nguồn lực cho việc chuẩn bị hồ sơ chứng từ và phản hồi rà soát.

Khung quy định chi trả sửa đổi của CMS đã tạo ra gánh nặng đào tạo đối với nhân viên và các nguồn giới thiệu bệnh nhân. Ban lãnh đạo đánh giá phần lớn công việc đó đã hoàn tất nhưng thừa nhận một số đối tác giới thiệu vẫn cần được hỗ trợ thêm trước khi giới thiệu bệnh nhân thở máy theo các quy định mới.

Biên lợi nhuận gộp có thể tiếp tục nhạy cảm với cơ cấu doanh thu khi mảng bán thiết bị và vật tư y tế có biên lợi nhuận thấp hơn chiếm tỷ trọng lớn hơn trong doanh thu. Công ty đang dựa một phần vào việc tiết kiệm chi phí từ nhà cung cấp và nhu cầu vốn thấp hơn để bù đắp tác động đó.

Điểm nhấn phiên hỏi đáp với chuyên gia phân tích

• Tái cung ứng vật tư điều trị giấc ngủ: Ban lãnh đạo kỳ vọng quý 4 sẽ mang lại mức tăng trưởng theo mùa mạnh nhất ở mảng tái cung ứng vật tư, nhờ sự gia tăng gần đây của các ca thiết lập máy PAP và bệnh nhân thuê máy.
• Định hướng biên lợi nhuận: Viemed đang ưu tiên tăng trưởng lợi nhuận ròng và dòng tiền tự do khi mảng bán hàng và dịch vụ ngày càng đóng vai trò quan trọng hơn. Ban lãnh đạo không đặt kế hoạch điều hành theo một mục tiêu biên EBITDA cứng nhắc, nhưng kỳ vọng biên lợi nhuận sẽ duy trì trên 20% trong thời gian tới.
• Bệnh nhân thở máy: Ban lãnh đạo cho rằng số lượng bệnh nhân vào cuối quý chững lại một phần là do yếu tố thời điểm và việc tạm giữ xuất hóa đơn liên quan đến tuân thủ. Công ty kỳ vọng số lượng bệnh nhân đang điều trị sẽ tăng so với quý trước trong quý 4 dựa trên các xu hướng hiện tại.
• Triển khai dịch vụ sức khỏe bà mẹ: Việc thâm nhập một bang mới chỉ đánh dấu sự khởi đầu của quá trình phát triển chứ chưa phải thị trường đã trưởng thành hoàn toàn. Viemed dự kiến thiết lập các hợp đồng với bên chi trả, bắt đầu tiếp thị kỹ thuật số và bổ sung nhân viên kinh doanh tại địa phương khi có thêm đà tăng trưởng.
• Chiến lược M&A: Ban lãnh đạo mô tả danh mục thương vụ tiềm năng vẫn đang hoạt động tích cực nhưng cho biết Viemed vẫn duy trì sự chọn lọc vì mở rộng tự thân thường ít tốn kém hơn. Các mục tiêu ưu tiên sẽ giúp mở rộng phạm vi địa lý, quan hệ với các bên chi trả hoặc mang lại dòng dịch vụ chăm sóc tại nhà mới.
• Chuyển đổi tiền mặt: Các khoản phải thu và chi phí trả trước cao hơn đã làm giảm dòng tiền quý 3. Ban lãnh đạo kỳ vọng việc thu tiền tốt hơn và các khoản thu tiền mặt liên quan đến chiết khấu sẽ hỗ trợ cải thiện tình hình trong quý 4.

Toàn văn biên bản cuộc gọi báo cáo kết quả kinh doanh

Toàn văn cuộc gọi công bố kết quả kinh doanh

Phần trình bày của ban lãnh đạo

Operator

Greetings. Welcome to the Viemed Healthcare Third Quarter 2026 Earnings Conference Call. [Operator Instructions] I'll now turn the conference over to Trey Fitzgerald, CFO. Thank you, Trey. You may begin.

Trae Fitzgerald

Thank you and good morning, everyone. Please note that our remarks in this conference call may include forward-looking statements under U.S. federal securities laws or forward-looking information under applicable Canadian securities legislation, which we collectively refer to as forward-looking statements. Such statements reflect the company's current views, intentions with respect to future results or events and are subject to certain risks and uncertainties which could cause actual results or events to vary from those indicated in forward-looking statements.

Examples of such risks and uncertainties are discussed in our disclosure documents filed with the SEC or the securities regulatory in certain provinces of Canada. Because of these risks and uncertainties, investors should not place undue reliance on forward-looking statements. Forward-looking statements made in this conference call are made as of today, and the company undertakes no obligation to update or revise any forward-looking statements except as required by law. The third quarter financial supplement and financial news release, as well as the related financial statements, are available on the SEC's website.

With that, I'll turn the call over to our Chief Executive Officer, Casey Hoyt.

Casey Hoyt

Thank you, Trey. Good morning, everyone, and thank you for joining us. Before getting into the results, I want to thank our roughly 1,500 employees. Their daily work with patients and referral partners is what makes our growth possible. I appreciate the care they provide and the work they put into serving more patients as Viemed continues to grow.

The third quarter was another strong quarter for Viemed, with a record revenue of $80.7 million, representing 12.2% growth over last year. Just as importantly, that growth translated into stronger earnings. Net income attributable to Viemed increased 32% year over year and approximately 68% from the second quarter. We're continuing to grow the business at a double-digit pace, demonstrating the earnings potential of the platform we've built.

For the 1st time since the Lehan acquisition, both the current and prior-year quarters include a full 3 months of Lehan's operations. That gives us a much clearer picture of our growth with the 12.2% increase reflecting expansion across our existing businesses rather than the incremental revenue contribution of an acquisition. Sleep therapy was a particular source of strength this quarter, and we're also seeing encouraging results from bringing maternal health services into our established Viemed markets.

Success in those initial maternal health markets gives us confidence to broaden the rollout. We are now on track to enter 2 additional states per quarter beginning in the fourth quarter, establishing a regular pace of expansion. Markets we have already entered are still early in their development. We see years of opportunity to build volume within each state as we develop referral relationships and reach more patients.

Each launch adds to that opportunity so growth can continue within our existing markets as we expand into new ones. Breast pumps and related supplies are a practical example of how we can do more with the capabilities already in the company. Lehan brought the specialized experience in this business. Viemed's existing payer relationships and reimbursement capabilities give us a way to extend it into markets we already know.

The early results have given us the confidence to take that next step. As we open those markets, we'll be paying close attention to fulfillment and reimbursement. We want the additional volume to become a productive part of the business with reliable service for mothers who depend on us. The 2-step cadence gives our teams a clear operating plan for the next stage.

Our growing sleep patient population shows how we're expanding Viemed's reach and serving more people. During the quarter, we served 43,861 PAP therapy patients, over 6,000 more than the second quarter, and 37.5% above a year ago. PAP setups also increased both sequentially and year-over-year. Growth is coming through in patients receiving therapy, as well as the activity bringing patients into care.

Resupply grew alongside that activity. We served 40,918 resupply patients, up approximately 22% from a year ago and 10.5% from the second quarter. Our expanding patient population creates further opportunity to grow resupply and increasing participation in the program is a priority. We are simplifying order processing to support that growth and make it easier for patients to receive supplies on time with the dependable service that keeps them engaged over the course of their therapy.

In ventilation, we have a longer revenue trend to assess under the revised CMS coverage rules issued in 2025. Ventilator rental revenue has increased in each quarter this year from $35.4 million to $36.4 million and now $37.5 million. The first 9 months was approximately 8% above the same period last year. The comparison is particularly meaningful because much of the comparable 2025 period preceded the new CMS coverage rules. Growing ventilation revenue against that comparison supports our confidence in our ability to expand the business under the new framework.

More broadly, we view the legislative and rulemaking environment as generally favorable to established providers that are invested in clinical care and compliance. Audit activity has increased across the DME industry, including for providers with strong compliance programs. Our own teams are spending more time and resources responding to those reviews. We are encouraged that CMS is examining its audit contractor model and has specifically asked how to reduce unnecessary provider burden and protect patient access.

We see an opportunity for more targeted, consistent oversight, and we intend to bring our experience to that discussion so providers can devote more of their resources to caring for patients. Our responsibility is to help patients receive the care they need. We support appropriate oversight and we will advocate for coverage policies and review processes that preserve timely access to medically necessary care. Our clinical teams see the needs of these patients every day, and we intend to make sure those needs remain part of the policy discussions.

The third quarter showed that we can grow the business under the new coverage framework and convert more revenue into earnings. We are serving more patients and the opportunities ahead in sleep and maternal health give us confidence as we enter the final quarter of the year. Todd will now discuss the financial results and operating priorities supporting our next phase of growth.

Todd Zehnder

All right, thank you, Casey, and good morning, everyone. All figures are in U.S. dollars, and our full results have been filed with the SEC. I'll refer to information included in the quarterly financial supplement, which is also available on our Investor Relations website. Net income attributable to Viemed was $4.6 million, or $0.11 per diluted share, compared with $3.5 million, or $0.09 per diluted share, a year ago, and $2.8 million, or $0.07 per diluted share, in the second quarter of this year.

Net income increased 32% year over year and approximately 68% from the second quarter. Adjusted EBITDA was $17.1 million, an increase of approximately 6% from the prior-year quarter and 24% sequentially. Adjusted EBITDA margin was 21.1% compared with 17.6% in the second quarter and 22.4% a year ago. The sequential margin expansion was approximately 350 basis points.

Revenue continued to grow this quarter and SG&A declined from the second quarter. Both contributed to the sequential increase in profitability with several compensation and benefit adjustments also affecting the results. Revenue increased 3.3% from the second quarter with growth across rentals, equipment and supply sales, and services. Other equipment rentals grew approximately 13.1% year over year, and equipment and supply sales grew approximately 23.7%, supported by sleep and women's health.

Ventilator rental revenue was $37.5 million, up 7.4% from a year ago, supported by higher average patient count. Gross profit was $46.2 million or 57.3% of revenue compared with 57.5% a year ago and 57.7% in the second quarter. Revenue from sales and services represented 32% of revenue compared with 30.1% a year ago. The year-over-year shift towards equipment and supply sales affects gross margin because these offerings generally carry lower margins than equipment rentals while also requiring less capital investment.

As we discussed last quarter, we added a new distribution partner that, together with our existing suppliers, gives us supplier capacity well beyond our current needs across all product lines to support future growth. We are still implementing the related cost savings and expect them to improve gross margin by approximately 50 basis points once fully in place. SG&A was $35.5 million, or 44% of revenue, compared with 47.5% in the second quarter and 44.4% a year ago.

SG&A declined approximately $1.6 million sequentially. Year over year, revenue grew faster than SG&A, even as we added resources to support the larger business. Lower compensation-related accruals and benefit expense contributed to the sequential decline. Phantom stock expense also came down substantially as expected following the large mark-to-market adjustment in the second quarter associated with the increase in our share price. Benefit rebates also reduced expense during the quarter.

Regular payroll and software spending increased as we added capacity to serve a growing patient population. That additional capacity is supporting higher volumes, including a 12% sequential increase in PAP resupply orders. At the same time, billing expense declined approximately 12% as revenue grew, reflecting the workflow changes and implementation timing. Our focus is on getting more volume through with the people and systems that we have in place.

Compliance is another area where our personnel and systems can provide a competitive advantage as oversight increases across the industry. Enforcement and claims audit activity have picked up and our teams are devoting more resources to those reviews. The documentation and follow-up work adds administrative and professional costs and in some cases can extend payment timelines. Our success rate under these audits remains very strong.

Those outcomes support our confidence in the care we provide and the documentation supporting it. Our teams are focused on submitting complete responses and moving reviews towards resolution. The increase in accounts receivable had several drivers this quarter. Audit-related payment timing was one contributor, alongside other billing and collection factors, including delays associated with system migrations. We believe the related revenue remains fully realizable.

These delays have extended the timing of cash collection and temporarily tied up more cash in working capital. Collections in October were extremely strong, so we are confident that this will work itself out during the fourth quarter. Operating cash flow was $11.5 million. After net CapEx of $7.5 million, free cash flow was $4 million. Net CapEx represented approximately 9.2% of revenue.

For the first 9 months of 2026, operating cash flow was $35.5 million and free cash flow was $15.2 million, compared with $33.5 million and $17.3 million, respectively, a year ago. Lower equipment sales proceeds also affected the year-to-date cash flow comparison, as the prior-year period benefited from the ventilator return program. On a trailing 12-month basis, free cash flow was approximately $26.1 million.

The business continues to generate cash after funding equipment needs, although the current quarter's collection timing reduced cash conversion. We continued to reduce debt and return capital during the quarter. We repaid approximately $2.1 million of term debt and repurchased and canceled 115,000 shares for approximately $1 million. At September 30, cash was $9.7 million and borrowings under our credit facility were $5.3 million with nothing on the revolver.

We made an additional $2 million term loan repayment in October, further reducing our outstanding debt. Our first use of capital is supporting the growth within Viemed, including the maternal health expansion and the needs of the larger sleep business. We retain the flexibility to consider acquisitions that fit our operations and return requirements and to repurchase shares when the value is attractive. The balance sheet allows us to evaluate those choices without committing to a fixed allocation among them.

Turning to our outlook, we are raising the lower end of our full-year revenue guidance and now expect revenue of $316 million to $320 million, compared with our previous range of $314 million to $320 million. We are narrowing our adjusted EBITDA guidance to $64 million to $66 million, compared with our previous range of $64 million to $68 million. With 9 months complete, the narrower range reflects our results through September and our updated expectations for the fourth quarter.

We are also lowering our net CapEx outlook to 8% to 9% of revenue, compared with 8.5% to 10% previously. Increasing contribution from less capital-intensive offerings reduces the equipment investment needed to support our growth. Our revised outlook anticipates sequential growth in both revenue and adjusted EBITDA in the fourth quarter and excludes any potential future acquisitions or strategic transactions.

As we finish the year, our operating priorities include improving collections and preparing the next maternal health markets for the rollout Casey described. We're seeing demand in the areas where we have added resources, and our job is to turn that activity into earnings and cash as the business grows. With that, we'll wrap up our prepared remarks and take your questions. Operator, please open the lines.

Operator

Thank you. We will now be conducting a question and answer session. [Operator Instructions] Our first question is from Ilya Zubkov with Freedom Broker. Please proceed with your question.

Phần hỏi đáp

Ilya Zubkov

First is on the sales side. I see that sleep resupply patients grew 10.5% sequentially, but equipment and supply sales grew only about 2%. I'm just wondering if the gap is timing, price mix, or the contribution from women's health, and how should we think about revenue per resupply patient from there?

Trae Fitzgerald

Yes. Hey, Ilya, good morning. Yes, when we think about the sales line, particularly in maternal health and resupply, you are correct. There was a strong 2Q. So if you're thinking about 3Q sequentially, I think the resupply was stronger. There's nothing that really comes to top of mind that was any sort of reduction off of 2Q other than 2Q was just a really strong quarter as well in that regard.

It sets the stage for really what we expect is probably our largest growth in 4Q will be in that line. You're going to see the best seasonality in 4Q for the sleep resupply side of the business, and further pull through in sort of that PAP therapy that we were talking about this quarter with increased setups and increased rental patients is going to transition to resupply in the back half of this year or the fourth quarter rather.

Ilya Zubkov

One on margin, please, if I may. As the sales mix shifts toward lower-margin, less capital-intensive lines, what financial KPIs are you targeting over the next 2 to 3 years, and what would you consider as a normalized margin framework?

Todd Zehnder

Well, I would say that we want to grow all the way down the line from an EBITDA and net income perspective. But I think as we do move into more sales and services and have no CapEx, net income growth probably becomes a little bit more important for us versus adjusted EBITDA. That also will translate into free cash flow, which you're hearing us talk a lot about because it's extremely important to us.

And I think our trailing 12 months, I said it was maybe $26 million to $27 million after growing organically this quarter 12.5%. So we're pretty pleased with that. We're not going to get too hung up on the exact EBITDA margin as we continue to move, but I definitely think we'll stay up in the 20-plus percent adjusted EBITDA for the time being.

Ilya Zubkov

Great. Thank you so much. I'll pass the line. Thanks.

Operator

Our next question is from Mike Petusky with Barrington Research. Please proceed with your question.

Unknown Speaker

Forgive me, I missed the first 5 minutes, so if you covered this, forgive me. But in terms of the vent patient number in the quarter, that to me looks a little soft and significantly down, and I'm just curious, is that a function of just sort of the higher hurdle, sort of service hurdle with the NCD, or can you speak to that? Is there anything to be concerned about in that patient number?

Casey Hoyt

Yes, I think you have a little bit of that, Mike, just with there's still an education process going on with the sales force and our referral partners. And so whenever you have change with how the approval process goes for these patients, sometimes you have some referral sources get a little bit gun-shy. However, I mean, the demand is there. I see that what's happening despite us going through those hurdles, the competitor appears to be struggling a little bit more than we are just because we're so narrowly focused in complex respiratory.

So I think there's market share to be gained here as we establish that baseline of education and look to the future of really getting to these patients. We know the patients are not going away. We're still in an underserved population. They're going in and out of the hospital. It's just our job to just continue to give these referral sources the confidence that, look, we can manage the compliance on these patients despite having all these new rules that the NCD has laid out. And so it's been a little bit of taking time to establish that new normal, but I would say that 80% of the work is done and we're excited about the patient population for the future.

Trae Fitzgerald

Yes, hey, and Mike, this is Trey. Let me add some context to that too. I think we talked about it in the prepared remarks, but that active patient count is a point in time. Sometimes it can be, especially in the NCD, where we have some kind of noise in some of the compliance-related active billing versus hold, and those sort of things. But in the quarter, we had higher active average patients throughout the quarter, and that's why you're seeing vent revenue growing sequentially, but the point in time, right at the end of the month, went down a little bit. So that created a little bit of noise. Always we think we're going to start to stack that up here in 4Q and into 2027.

Unknown Speaker

So, I mean, would you expect sort of a sequential increase in 4Q versus 3Q? Because last year you guys actually saw a slight decline from 3Q to 4Q in terms of vent patients. Given what you just said, I mean, would you expect maybe a slight bump in 4Q versus 3Q?

Todd Zehnder

That's the trends we're seeing right now, Mike. Yes, we do expect that. And I just think that with all the change that's going on, whether it's NCD-related or other changes going on, I think the vent active patient count has been a little bit more wobbly and, obviously, we've gotten a lot bigger, but yes, the current trends are showing that we will be back up in the fourth quarter.

Unknown Speaker

Okay, and then just 1 more, and I'll let other folks have a shot here. And again, forgive if I missed this, but in terms of the maternal health piece, did you guys talk at all or could you talk about progress you're making in terms of turning on states or your progress in sort of getting a plan together for turning on states over the next year? Could you just speak to sort of where you are in that rollout? Thanks.

Casey Hoyt

Yes, I mean, I'm not going to go into the particular states, but it's going to be a 2-state cadence. And we've already established our fulfillment partner, which has been a huge win in terms of creating the operational efficiencies for Lehan and their team. We're leading the maternal health sector to really scale. Our network development team is in a good spot where they're moving ahead into the next states with establishing the contracts and making sure that reimbursement is where it needs to be before we go into a particular state. We've been analyzing a lot of data on expecting mothers and birth rates and things of that nature for those particular states to where we go into the right ones first.

So our team is really excited about the sales force that we've been dropping in behind some of these states. You know, we're seeing higher conversion rates from those referral partners that the sales folks or boots on the ground calling on. You know, you put the technology in place where you're getting in front of expecting mothers that leave. And so, you know, they're driving a good portion of the sales as we get those contracts up and running. So that's a brand new model, if you will, to Lehan. So, yes, hands built, and then you double down with some boots on the ground, and you improve those conversion rates, and you got the right states and the right reimbursement, it's a recipe for success. We're super excited about it. We expect to continue to grow it.

Unknown Speaker

All right, terrific. Thanks, guys.

Operator

[Operator Instructions] Our next question is from Dave Storms with Stonegate. Please proceed with your question.

David Storms

Maybe just wanted to stick with the maternal health rollout there. Do you have any further comments on what we should expect in terms of growth curves? I know you've mentioned 2 states per quarter, sounds like. Should those states be pretty much fully developed after that quarter, or is that just to get them on their feet before moving to the next 2 states?

Casey Hoyt

I mean, I can start, if you can finish on the growth rate. No, they for sure will not be fully developed within that quarter. That's just the onboarding process. So, for example, you know, we did add, like, Texas as our first state. I mean, we're still doing so much work in Texas. That was last year. So it's just a ramp up of having new hunting ground to go into. But it does, the business does start coming in almost immediately just because of the technology that we have and the marketing that we do in those current states. But then you have a growth strategy after that where you drop it in boots on the ground and really getting better at conversions and so on and so forth. So, yes, that cadence is really just new hunting ground, and it'll be increasing along the way throughout the year.

Todd Zehnder

Yes, I'll just, I mean, kind of exactly what Casey said. You start out, you have hopefully most of the contracts, but you don't have all of them. You start with digital marketing. And then as you gain traction, you put more personnel there. So the growth curve definitely takes some time. We've seen growth consistently throughout the year in Texas, and we just now started 2 other states. So we would expect that to happen, and the cadence will continue. Like Casey said in his remarks, a state or 2 every quarter going forward. So it will continue ramping over time is the short answer.

David Storms

That's great clarity. I appreciate that. Sticking with that, you mentioned in your answer there the boots on the ground are going to be important and the people there are going to be important. I know in the past we've talked about sales force training, maybe any updates there on how that's progressing, what you're seeing, what kind of efficiencies that could be driving.

Casey Hoyt

Are you talking specifically maternal?

David Storms

Specifically maternal, but also if you want to expand that to the rest of the business.

Casey Hoyt

Yes, I mean the training is very important to us. We feel like the better our training gets, the more efficient all of our new sales reps onboard new patients. So we're constantly dumping resources into further training. The breast pump sale is really, it's way easier, if you will, than it is to train a complex respiratory rep. And so, you're basically chasing that order and making sure that you have the appropriate documentation in place to authorize billing. And so when you have some help with some people to chase some of those things down that technology can't do, your conversion rates in those particular states go up. But from a sales standpoint, it's a pretty easy sell. You just got to find somebody who likes to work hard and stay busy and stay in front of these referral partners.

David Storms

That's perfect. I appreciate that. One more, if I could sneak it in. I know you mentioned in the prepared remarks that you have a strong balance sheet that gives you optionality for additional M&A. Just any thoughts as to what you're seeing on this front? Would that take the shape of another Lehan? You know, is there a target profile you would think about, anything like that?

Casey Hoyt

The pipeline is active. I mean, look, here's another way of looking at it. Last year we looked at over 40 deals and we passed on them. You know, the reason that you'll see us pass on these deals is because it's less expensive for us to go in and organically grow next to them versus purchasing them. And so it takes a unique approach. Acquisitions such as Lehan, such as HMP, which has perhaps a geographic coverage gap or maybe some insurance contracts that we don't have or a new service line like Lehan did for us to get really hot to trot about the M&A game, but make no mistake about it, they're out there and we look at them constantly. It's just we're pretty darn picky because we organically grow so much faster and it's just more efficient to do it that way than going in and spending too much money.

Todd Zehnder

Yes, and I'd say that to add to that, the reasons for M&A really haven't changed in the priorities and the requirements. Basically, treating patients in the home is the first and really the most important. And then, like Casey said, if we can get geographic expansion, payer expansion, or even like we've proved out the product expansion, those are the priorities with M&A. We don't need to go acquire another vent company in an area that we have a lot of success in. That's our organic model, and we believe firmly in that.

David Storms

Understood. Thank you for taking my questions and good luck in the next quarter.

Todd Zehnder

Thanks, Dave.

Operator

Our next question is from Andrew Graham with Odinson Partners. Please proceed with your question.

Unknown Speaker

Can you just repeat your comment as it related to cash flow? I think you said maybe a little bit of a hang-up on the accounts receivable side.

Todd Zehnder

Yes. So we had higher AR. I mean, if you look on the balance sheet, I want to say it was $35 million at the end of the quarter. Due to a few different things, some were just like October 1 was one of the better days we've had, some things that should have been collected in September. We had some audit things that slowed down cash. That has resolved itself in October and the beginning of November. And those are the 2 main ones. And actually another, a private payer audit that looks like it's resolving itself. So when you have that, it actually doesn't hurt your earnings or your EBITDA, but it does slow down cash flow conversion. So fourth quarter will make that up, but it's why the third quarter was sort of uniquely low.

Unknown Speaker

Was there also something else going on? I'm not looking at it, but was it my recollection, was prepaid expense a drag as well in the quarter?

Trae Fitzgerald

Yes, prepaid expense was a drag during the quarter. Some of it is just timing of temporary timing for the year, Andrew. All of our kind of tech renewals, insurance, all those things we pay annually up front and it goes into prepaid in the third quarter. We also had some year-end or not year-end, but sort of fiscal year-end for some of these programs for our self-health insurance, pharmacy rebates and other product rebates that will convert to cash into the fourth quarter. So it is a part that contributed to 3Q, but it's also a dynamic that traditionally exists in 3Q.

Todd Zehnder

A little bit more pronounced this year. Yeah, prime example is we prepay all of our workers' comp, D&O, all of our insurance, instead of financing it over a year, just because we get a good rate of return by paying it and we have the cash. Same thing for like Trey's talking about some of these technology licenses, if we pay them all up front, we get a discounted rate. So we'd rather use our cash and take a higher expense.

Unknown Speaker

Okay, but just to clarify, that was a little bit higher this year, the drag was a little bit higher this year versus last year?

Trae Fitzgerald

Mildly higher, but I wouldn't say it's materially higher.

Unknown Speaker

Okay. All right. And then can you clarify your comment on the business, I think you said you're about 80% complete. Are you referring to kind of the training and education of the referral sources or just kind of clarify that comment?

Casey Hoyt

Yes, that's an anecdotal gut feeling, Andrew, so just keep that in mind. I'm just saying that's the way it feels out there in the marketplace whenever you're talking to referral sources on education. We're still, for the most part, up to speed on the NCD and new rules and the new landscape, but you still run into your roughly 20% of folks that you have to double down on education and so on and so forth. So that's just a gut feeling to take that with a grain of salt.

Unknown Speaker

All right. Thanks a lot, you guys. Appreciate the time.

Casey Hoyt

All right, Andrew.

Operator

We have reached the end of the question and answer session. I would like to turn the floor back over to management for closing comments.

Unknown Speaker

Okay. Thank you for joining us today. We appreciate all the questions and look forward to continue to grow Viemed. We appreciate y'all's trust. Hope everyone has a nice day. Take care.

Operator

We have reached the end of the conference. You may disconnect your lines at this time. Thank you for your participation.

This live transcript is auto-generated without human intervention or review.